Navigation Links
USPTO Issues Patent for CardioGenics' Signal Amplification Technology
Date:6/29/2011

MISSISSAUGA, Ontario, June 29, 2011 /PRNewswire/ -- CardioGenics Holdings Inc. (CGNH.OB) announced today that the United States Patent & Trademark Office (USPTO) has notified the company that its patent application has been granted (issued patent # 7,964,415). This patent covers CardioGenics Inc.'s proprietary signal amplification technology, which is a key component of the core technology for CardioGenics' Ultra-Sensitive QL Care™ Analyzer. CardioGenics' unique methodology for signal amplification enables a decrease in the amount of binding reagents used in immunoassay diagnostic tests, such as those to be performed on the QL Care™ Analyzer, which, in turn, results in improved signal-to-noise ratio thereby increasing testing sensitivity.

"We are very pleased that the USPTO has recognized the unique nature of CardioGenics' signal amplification technology," said Dr. Yahia Gawad, CEO of CardioGenics. "This patent is an important addition to our patent portfolio since it addresses a key component of the technology that permits the ultra-sensitive performance of our QL Care™ Analyzer," continued Dr. Gawad.

About CardioGenics Holdings Inc.

Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's proprietary microspheres technology and SAVAsphere magnetic beads are developed and marketed through the Company's Luxspheres subsidiary. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com and www.luxspheres.com.

Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.


'/>"/>
SOURCE CardioGenics Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO
2. USPTO Allows NivaSonix Core Patent - External Ultrasound Lipoplasty
3. KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Companys ADHD Prodrug Technology
4. KemPharm, Inc. Receives Notice of Issuance From USPTO on Patent Protecting Companys ADHD Prodrug Technology
5. Endo Pharmaceuticals Issues Voluntary, Nationwide Recall of Two Lots of Endocet® (Oxycodone/Acetaminophen, USP) Tablets, 10 Mg /325 Mg
6. Preliminary Results of a Large Scale Study Show ConvaTec Moldable Technology™ Skin Barriers Help to Prevent and Improve Peristomal Skin Issues in Ostomy Patients
7. Health Information Technology: UC San Diego New Seminar Explores Four Critical Issues
8. FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System
9. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
10. United Kingdoms National Institute for Health and Clinical Excellence Issues Guidance on Percutaneous Tibial Nerve Stimulation for Faecal Incontinence
11. BD Issues 2010 Sustainability Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016 Potrero ... system, is pleased to announce the appointment of George ... San Antonio, TX , WellMed is ... servicing over 200,000 patients and HMO members in ... founding WellMed in 1990 out of his own internal medicine ...
(Date:2/11/2016)... Ore. , Feb. 11, 2016 Wellpartner, ... announce the acquisition of SolutionsRx, a full-service 340B company ... Along with providing traditional contract pharmacy services, SolutionsRx also ... clients in navigating the complex 340B regulatory environment. ... --> James R. Love , CEO of ...
(Date:2/11/2016)... , Ill. and INDIANAPOLIS , Feb. 11, ... many young people, but for those with type 1 ... do these students juggle class schedules, assignments and campus ... with type 1 diabetes. On top of that, many ... Diabetes Scholars Foundation (Foundation) Lilly Diabetes ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... The ... among the top five firms in the “2015/2016 Best in KLAS: Software and ... Staffing. KLAS is a research and insights firm on a global mission to ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... advocates will discuss how to improve care by making data on heart procedures ... disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital Heart ...
(Date:2/11/2016)... ... ... In a new paper published in the latest issue ... Rohrich, and colleagues, examine and underscore the importance of upper lateral cartilage in ... this vital area. , The upper lateral cartilage in rhinoplasty, refers to a ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... unparalleled clinical decision support technology, with highly adaptable algorithms, has been updated to ... patient has signs and symptoms consistent with Zikas and a travel history to ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... motivational speaker, trainer and author Ray Clarke poses a question as a challenge ... . In his book, "Being in the Being" (published by Partridge Singapore), Clarke ...
Breaking Medicine News(10 mins):